In vitro activity of moxifloxacin against respiratory pathogens in Latin America;Actividad in vitro de moxifloxacino frente a patógenos respiratorios en iberoamérica

Revista Espanola de Quimioterapia

Volumn 15, Issue 4, 2002, Pages 325-334

  Lopez H ^a   Sader, H ^b   Amabile C ^c   Pedreira, W ^d   Munoz Bellido J L ^e   Garcia Rodriguez J A ^e   Garcia P ^f   Prado, V ^f   Robledo, J ^f   Sussmann, O ^f   Blandon, Y ^f   Diaz P ^f   Ponce, G ^f   Quinones F ^f   Fagundo, R ^f   Akle, D ^f   Barriga, G ^f   Guillen A ^f   Zerpa, R ^f   Bauer, J L ^f   Comegna, M ^f   Gallegos, B ^f   more..

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Fundacion LUSARA   (Mexico)

^d Ctro Asist Sindicato Med Uruguay   (Uruguay)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f Hospital Universitario de Salamanca ^*

Author keywords

Fluoroquinolones; Latin American; Moxifloxacin; Respiratory tract infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFUROXIME; CLARITHROMYCIN; COTRIMOXAZOLE; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CENTRAL AMERICA; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; RESPIRATORY TRACT INFECTION; SOUTH AMERICA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; FLUOROQUINOLONES; HAEMOPHILUS INFLUENZAE; HUMANS; LATIN AMERICA; MORAXELLA (BRANHAMELLA) CATARRHALIS; QUINOLINES; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 18544411595     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Bartlett, J.G., Dowell, S.F., Mandell, L.A., File, T.M., Musher, D.M., Fine, M.J. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-382.
2. Álvarez, F., Bouza, E., García-Rodríguez, J.A. y cols. Uso de antimicrobianos en la exacerbación de la enfermedad pulmonar obstructiva crónica. Rev Esp Quimioterap 2001; 14: 87-96.
3. Frías, J., Gomis, M., Prieto, J. y cols. Tratamiento antibiótico empírico inicial de la neumonía adquirida en la comunidad. Rev Esp Quimioterap 1998; 11: 255-261.
4. Grupo de Trabajo de la Asociación Latinoamericana del Tórax (ALAT). Recomendaciones ALAT sobre la neumonía adquirida en la comunidad. Arch Esp Bronconeumol 2001; 37: 340-348.
5. Grupo de Trabajo de la Asociación Latinoamericana del Tórax (ALAT). Recomendaciones ALAT sobre la exacerbación infecciosa de la EPOC. Arch Esp Bronconeumol 2001; 37: 349-357.
6. Jones, R.N., Pfaller, M.A. Bacterial resistance: A worldwide problem. Diagn Microbiol Infect Dis 1998; 31: 379-388.
7. Koeth, L.M., Jacobs, M.R., Bajaksouzian, S., Zilles, A., Lin, G., Appelbaum, P.C. Comparative in vitro activity of gemifloxacin to other fluoroquinolones and non-quinolone agents against Streptococcus pneumoniae. Haemophilus influenzae and Moraxella catarrhalis in the United States in 1999-2000. Int J Antimicrob Agents 2002; 19: 33-37.
8. López, H., Vilches, V., Scarano, S. y cols. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens. Int J Antimicrob Agents 2001; 18: 379-382.
9. Sheng, W.H., Wang, J.T., Chen, Y.C., Chang, S.C., Luh, K.T. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan. J Microbiol Immunol Infect 2001; 34: 178-184.
10. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-fifth ed. NCCLS document M7-A5. NCCLS, Pennsylvania, USA, 2000.
11. Pérez Trallero, E., García Rey, C., Martin Sánchez, A.M., Aguilar, L., García de Lomas, J., Ruiz, J. and the Spanish Surveillance Group for Respiratory Pathogens (SAUCE Program). Activities of six different quinolones against clinical respiratory isolates of Streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain. Antimicrob Agents Chemother 2002; 46: 2665-2667.
12. Nagai, K., Appelbaum, P.C., Davies, T.A. y cols. Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 Central and Eastern European countries. Antimicrob Agents Chemother 2002; 46: 546-549.
13. Pérez Trallero, E., Fernández Mazarrasa, C., García Rey, C. y cols. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: Results of a 1-year (1998-1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001; 45: 3334-3340.
14. Critchley, I.A., Sahm, D.F., Thornsberry, C., Blosser Middleton, R.S., Jones, M.E., Karlowsky, J.A. Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999. Diagn Microbiol Infect Dis 2002; 42: 129-135.
15. Amabile Cuevas, C.F., Hermida Escobedo, C., Vivar, R. Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes. Clin Infect Dis 2001; 32 (Suppl. 1): S30-32.
16. Hoban, D.J., Doern, G.V., Fluit, A.C., Roussel-Delvallez, M., Jones, R.N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001; 32 (Suppl. 2): S81-S93.
17. Karlowsky, J.A., Jones, M.E., Draghi, D.C., Critchley, I.A., Thornsberry, C., Sham, D.F. In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporins cefditoren. Diagn Microbiol Infect Dis 2002; 42: 59-64.
18. Calvo, A., Amores, R., Valero, E., Sevillano, D., Prieto, J. Actividad de distintos antimicrobianos frente a Streptococcus pneumoniae resistentes a la penicilina. Rev Esp Quimioterap 2001; 14: 345-350.
19. Pfaller, M.A., Jones, R.N., Doern, G.V, Sader, H.S., Kugler, K.C., Beach, M.L. Survey of blood stream infections attributable to gram positive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada and Latin America from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 1999; 33: 283-297.
20. Schmitz, F.J., Perdikouli, M., Beeck, A., Verhoef, J., Fluit, A.C. Molecular surveillance of macrolide, tetracycline and quinolone resistance mechanisms in 1191 clinical European Streptococcus pneumoniae isolates. Int J Antimicrob Agents 2001; 18: 433-436.
21. Ho, P.L., Yung, R.W., Tsang, D.N. y cols. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: Results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001; 48: 659-665.
22. Bassetti, M., Dembry, L.M., Farrel, P.A., Callan, D.A., Andriole, V.T. Comparative antimicrobial activity of gatifloxacin with ciprofloxacin and betalactams against gram positive bacteria. Diagn Microbiol Infect Dis 2001; 41: 143-148.
23. Lina, G., Quaglia, A., Reverdi, M.E., Leclerq, R., Vandenesch, F., Etienne, J. Distribution of genes encoding resistance to macrolides, lincosamides and streptogramins among staphylococci. Antimicrob Agents Chemother 1999; 43: 1062-1066.
24. Muñoz Bellido, J.L., Alonso Manzanares, M.A., Yagüe Guirao, G. y cols. In vitro activities of 13-fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates. Antimicrob Agents Chemother 1999; 43: 966-968.
25. Schmitz, F.J., Jones, M.E., Hofmann, B. y cols. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC. Antimicrob Agents Chemother 1998; 42: 1249-1252.
26. Thornsberry, C., Ogilvie, P., Kahn, J., Mauriz, Y. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn Microbiol Infect Dis 1997; 29: 249-257.
27. Ritcher, S.S., Brueggemann, A.B., Huyhn, H.K. A 1997-98 national surveillance study; Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 United States institutions. Int J Antimicrob Agents 1999; 13: 99-107.
28. Felmigham, D., Gruneberg, R.N. The Alexander Project 1996-97: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45: 191-203.